Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sardocor Corp. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to 1 distinct examiner and 1 distinct art unit, indicating a narrow and specific focus for the company's current patent office interactions. The presence of only 1 pending office action suggests a limited volume of active applications requiring immediate response.
The busiest examiner for this portfolio is TATGE, LEXUS MARC, who is currently handling the 1 pending office action. As there is only 1 distinct examiner involved, the company's immediate prosecution success in the Biotechnology & Pharmaceuticals sector relies on the specific feedback from TATGE, LEXUS MARC. The use of 1 distinct art unit further concentrates the regulatory environment, as the company does not currently face multiple sets of art unit-specific guidelines.
With 1 pending office action assigned to 1 distinct examiner, the administrative burden is minimal but highly centralized. TATGE, LEXUS MARC, as the busiest examiner with 1 pending action, is the sole point of contact for the company's current pending matters. This profile, characterized by 1 distinct art unit and 1 pending office action, reflects a singular point of focus for Sardocor Corp. during the current prosecution cycle.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260456 | METHODS AND COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | TATGE, LEXUS MARC | 32d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260456 | METHODS AND COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | TATGE, LEXUS MARC | 1637 | §103 | Final Rejection | 32d overdue | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial